Immunomodulatory effects
No significant differences were observed in the levels of inflammatory cytokines on days 0, 2, and 5 between the two treatment groups. However, interleukin-6 (IL-6) levels showed a greater decrease in the sotrovimab group between days 2–5 and 0–14. On day 14, the CPT-FPV-treated group showed higher monocyte chemoattractant protein-1 (MCP-1) levels than sotrovimab (Table S9).